atile sulfur compounds including hydrogen sulfide, methanethiol, and dimethyl sulfide. A case report showed that oral ulcerations improved after the administration of infliximab in Crohn' s disease, 7 which might contribute to the improvement of intraoral halitosis.However, we hold a different perspective. In a pilot study conducted by the author in East China on 53 patients with active ulcerative colitis, we found over two-fifths of the ulcerative colitis patients also had extraoral halitosis. Moreover, their organoleptic score of extraoral halitosis significantly decreased after 1 week of mesalazine-based therapy. 8 These results imply that extraoral halitosis in IBD has a distinct pathogenesis. One possible explanation is that the overgrown gut bacteria in IBD can produce over amount of volatile sulfur compounds. 6 These compounds are absorbed by the gut. Although hydrogen sulfide and methanethiol are highly reactive and quickly metabolized by the intestinal mucosa, the inactive dimethyl sulfide can pass through the colon epithelium, enter the bloodstream, be transported through the circulatory system to the lung and exhaled into the air, resulting in elevated levels of dimethyl sulfide in the breath. 5 Therefore, extraoral halitosis in IBD should be referred to as "blood-borne extraoral halitosis. " 5 The mesalazine-based therapy inhibits the overgrowth of gut bacteria and subsequently reduces the production of dimethyl sulfide in the gut, showing a beneficial effect on improving extraoral halitosis in IBD.In conclusion, extraoral halitosis in IBD is underestimated and deserves more attention from IBD practitioners.